Matt is a member of Newton’s equity research team. Matt is responsible for covering the healthcare sector, specifically biopharmaceutical and medical-technology companies, and managing portfolios in the Smart Cures Innovation strategy.
- Joined industry
- 2000
- Joined the Group
- 2015
Strategy focus
Matt joined Newton in September 2021, following the integration of Mellon Investments Corporation’s equity and multi-asset capabilities into the Newton Investment Management Group. Before joining Newton, Matt was a senior research analyst at Mellon Investments Corporation and The Boston Company Asset Management (both BNY Mellon group companies).
Prior to joining BNY Mellon, Matt served as a portfolio manager and analyst covering the healthcare sector at Balyasny Asset Management. Prior to that, he managed global long/short equity healthcare hedge funds and covered the pharmaceuticals, biotechnology and healthcare services industries at Lehman Brothers/Barclays Capital. Prior to joining the investment industry, Matt was a senior research scientist at SmithKline Beecham.
Matt has a BS in Biology from Tulane University and an MBA from New York University.